Unknown

Dataset Information

0

Effect of Food on the Pharmacokinetics of Quizartinib.


ABSTRACT: Quizartinib is an oral, highly potent, and selective type II FMS-like tyrosine kinase 3 inhibitor in development for acute myeloid leukemia. This parallel-group study evaluated potential food effects on quizartinib absorption in healthy subjects who received a single 30-mg dose after overnight fasting (n = 34) or a high-fat, high-calorie meal (n = 30). Blood samples were collected through 504 hours after dosing, and pharmacokinetic parameters calculated were maximum observed concentration (Cmax ) and area under plasma concentration-time curve from time 0 to last quantifiable concentration (AUClast ) and from time 0 to infinity (AUCinf ). Mean quizartinib pharmacokinetic profiles were similar under fasted and fed conditions. The geometric least squares means ratios (%) for fed/fasted and associated 90% confidence intervals (CIs) for Cmax , AUClast , and AUCinf were 91.58 (82.15-102.08), 105.39 (90.79-122.35), and 108.39 (91.54-128.34), respectively. The 90%CI for the ratio fell within the 80% to 125% limits for Cmax and AUClast , with 90%CI for AUCinf slightly outside the limits (ie, 128%). Food delayed quizartinib time to Cmax by 2 hours. All adverse events were either mild or moderate; no discontinuations due to adverse events occurred. Based on these results, quizartinib can be administered without regard to food.

SUBMITTER: Li J 

PROVIDER: S-EPMC7027461 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effect of Food on the Pharmacokinetics of Quizartinib.

Li Jianke J   Holmes Melissa M   Kankam Martin M   Trone Denise D   Mendell Jeanne J   Gammon Guy G  

Clinical pharmacology in drug development 20200108 2


Quizartinib is an oral, highly potent, and selective type II FMS-like tyrosine kinase 3 inhibitor in development for acute myeloid leukemia. This parallel-group study evaluated potential food effects on quizartinib absorption in healthy subjects who received a single 30-mg dose after overnight fasting (n = 34) or a high-fat, high-calorie meal (n = 30). Blood samples were collected through 504 hours after dosing, and pharmacokinetic parameters calculated were maximum observed concentration (C<sub  ...[more]

Similar Datasets

| S-EPMC6768889 | biostudies-literature
| S-EPMC8246815 | biostudies-literature
| S-EPMC5351008 | biostudies-literature
| S-EPMC6710528 | biostudies-literature
| S-EPMC5833862 | biostudies-other
| S-EPMC6177703 | biostudies-other
| S-EPMC5238805 | biostudies-literature
| S-EPMC6863819 | biostudies-literature
| S-EPMC6618047 | biostudies-literature
| S-EPMC6738372 | biostudies-literature